Company Performance Metrics
Reduce drug development costs and improve patient safety and drug efficacy with the next evolution of artificial intelligence - emergent intelligence.
The estimated average cost of drugs reaching market approval is close to $2.6 billion according to the Tufts Center for the Study of Drug Development’s (CSDD). Emergent Systems Analytics, helps
pharmaceutical and nutraceutical companies better target the best ingredient combination at the beginning of the product development life cycle, & gain insight into effectiveness, contraindications & side-effects before testing. ESAs emergent intelligence solutions can reduce fail rate & cost at every phase of development, potentially saving millions of dollars in development cost. It gets pharmaceutical and nutraceutical products to market faster.
